{"id":27995,"date":"2022-04-19T07:00:00","date_gmt":"2022-04-19T07:00:00","guid":{"rendered":"http:\/\/058b80091a3c605c01e88f8801310703"},"modified":"2024-11-03T15:13:41","modified_gmt":"2024-11-03T15:13:41","slug":"activity-of-alectinib-for-alk-rearranged-metastatic-solid-tumours-other-than-nsclc","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/activity-of-alectinib-for-alk-rearranged-metastatic-solid-tumours-other-than-nsclc\/","title":{"rendered":"Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC"},"content":{"rendered":"

In patients included in MyPathway, a multi-basket study assessing approved therapies in non-indicated advanced solid tumours with relevant alterations, alectinib showed activity in patients with ALK<\/em>–<\/em>rearranged advanced solid tumours other than non-small cell lung cancer (NSCLC). As in NSCLC, cancers with AL<\/em>K <\/em>mutations or amplification were not responsive to ALK inhibition. Adverse events were consistent with the known alectinib safety profile. Findings were presented by Dr. Funda Meric-Bernstam of the University of Texas MD Anderson Cancer Center in Houston, TX, US on behalf of MyPathway colleagues at 2022 AACR Annual Meeting (8-13 April, New Orleans, US).<\/p>\n

The study team analyzed alectinib activity and safety in a pan-tumour population with ALK<\/em> alterations included in MyPathway study (NCT02091141). Enrolled patients were at least 18 years old and had metastatic tumours with ALK<\/em> gene rearrangements, putative activating non-synonymous ALK<\/em> mutations, and\/or ALK<\/em> gene amplification. All patients received alectinib.<\/p>\n

The primary endpoint was investigator-assessed objective response rate (ORR) that comprised a complete response (CR) plus partial response (PR). Other endpoints included duration of response (DoR), disease control rate (DCR) defined as a CR plus PR plus stable disease (SD) longer than 4 months, progression-free survival (PFS), and safety.<\/p>\n

Until 18 November 2021 as a data cut-off, 21 patients with various tumour types have been enroled and treated. Among included patients, 11 (52.4%) had ALK<\/em> mutations or amplification and 10 patients (47.6%) had ALK<\/em> rearrangements with or without other ALK<\/em> alterations. Patients received a median of 2 (range, 1-5) prior lines of therapy.<\/p>\n

In 10 patients with ALK<\/em> rearrangements, there were 3 PRs (30.0%) in one patient with melanoma, papillary urothelial carcinoma, and colon adenocarcinoma each and fusion gene partners in those tumours were EMILIN1<\/em>, DCTN1<\/em>, and DIAPH2<\/em>; <\/em>a median DoR was 6.8 months. Additionally, 3 patients (with colon adenocarcinoma, uterine leiomyosarcoma, and pancreatic adenocarcinoma) in this group had SD longer than 4 months, one of those had also ALK<\/em> amplification, and fusion gene partners were STRN<\/em>, IGFBP5<\/em>, and EML4<\/em>; DCR was 60.0%. However, there were no responses among the 11 patients with ALK<\/em> mutations or amplification.<\/p>\n

Confirmed ORR for the entire group was 14.3% (in 3 of 21 patients), and DCR was 42.9% (in 9 of 21 patients). Median PFS was 8.2 months in patients with ALK<\/em> rearrangements versus 1.8 months for those with other ALK<\/em> alterations.<\/p>\n

Alectinib-related adverse events were observed in 85.7% of patients, with 3 (14.3%) experiencing grade 3 adverse events (anaemia, hypokalaemia, and changes in AST, ALT, and\/or blood creatinine levels). Adverse events were consistent with the known alectinib safety profile.<\/p>\n

The authors concluded that although the number of included patients was small, alectinib showed activity in patients with ALK<\/em>-rearranged advanced solid tumours, other than NSCLC.<\/p>\n

Reference<\/h4>\n

Swanton C, Friedman CF, Sweeney CJ, at al.<\/em> Activity and safety of alectinib for ALK-altered solid tumors from MyPathway<\/a>. Presented at 2022 AACR Annual Meeting (8-13 April, New Orleans, US).<\/p>\n

 <\/h2>\n

Source<\/a><\/p>","protected":false},"excerpt":{"rendered":"

In patients included in MyPathway, a multi-basket study assessing approved therapies in non-indicated advanced solid tumours with relevant alterations, alectinib showed activity in patients with ALK–rearranged advanced solid tumours other than non-small cell lung cancer (NSCLC). As in NSCLC, cancers with ALK mutations or amplification were not responsive to ALK inhibition. Adverse events were consistent […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-27995","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=27995"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27995\/revisions"}],"predecessor-version":[{"id":44957,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/27995\/revisions\/44957"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=27995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=27995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=27995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}